300294 博雅生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.6881.5105.3623.2746.168
总资产报酬率 ROA (%)0.6051.3244.8922.9945.522
投入资产回报率 ROIC (%)0.6601.4365.2043.2336.081

边际利润分析
销售毛利率 (%)44.20649.89464.65452.75854.657
营业利润率 (%)0.8485.31427.50913.39519.291
息税前利润/营业总收入 (%)-2.2424.13826.06112.18818.368
净利润/营业总收入 (%)7.9075.47022.8569.35716.148

收益指标分析
经营活动净收益/利润总额(%)843.017308.29395.379159.564100.786
价值变动净收益/利润总额(%)-700.29180.65616.46328.2018.240
营业外收支净额/利润总额(%)-59.381-5.3370.096-0.428-0.034

偿债能力分析
流动比率 (X)7.1705.0636.74114.0828.611
速动比率 (X)5.7104.0995.41512.8627.665
资产负债率 (%)10.14913.76010.8726.4909.316
带息债务/全部投入资本 (%)1.8633.8612.5180.8300.708
股东权益/带息债务 (%)5,209.7352,455.0633,788.90111,905.02713,936.386
股东权益/负债合计 (%)885.125626.602819.7171,440.684960.198
利息保障倍数 (X)0.808-4.566-17.680-10.600-20.046

营运能力分析
应收账款周转天数 (天)219.616108.03168.30145.58059.165
存货周转天数 (天)505.534347.471455.674175.840193.372